umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tissue-specific dysregulation of cortisol regeneration by 11 beta HSD1 in obesity: has it promised too much?
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine.
2014 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 57, no 6, 1100-1110 p.Article, review/survey (Refereed) Published
Abstract [en]

Cushing's syndrome, caused by increased production of cortisol, leads to metabolic dysfunction including visceral adiposity, hypertension, hyperlipidaemia and type 2 diabetes. The similarities with the metabolic syndrome are striking and major efforts have been made to find obesity-associated changes in the regulation of glucocorticoid action and synthesis, both at a systemic level and tissue level. Obesity is associated with tissue-specific alterations in glucocorticoid metabolism, with increased activity of the glucocorticoid-regenerating enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1) in subcutaneous adipose tissue and decreased conversion of cortisone to cortisol, interpreted as decreased 11 beta HSD1 activity, in the liver. In addition, genetic manipulation of 11 beta HSD1 activity in rodents can either induce (by overexpression of Hsd11b1, the gene encoding 11 beta HSD1) or prevent (by knocking out Hsd11b1) obesity and metabolic dysfunction. Taken together with earlier evidence that non-selective inhibitors of 11 beta HSD1 enhance insulin sensitivity, these results led to the hypothesis that inhibition of 11 beta HSD1 might be a promising target for treatment of the metabolic syndrome. Several selective 11 beta HSD1 inhibitors have now been developed and shown to improve metabolic dysfunction in patients with type 2 diabetes, but the small magnitude of the glucose-lowering effect has precluded their further commercial development. This review focuses on the role of 11 beta HSD1 as a tissue-specific regulator of cortisol exposure in obesity and type 2 diabetes in humans. We consider the potential of inhibition of 11 beta HSD1 as a therapeutic strategy that might address multiple complications in patients with type 2 diabetes, and provide our thoughts on future directions in this field.

Place, publisher, year, edition, pages
2014. Vol. 57, no 6, 1100-1110 p.
Keyword [en]
11 beta-Hydroxysteroid dehydrogenase type 1, 11 beta HSD1 inhibitors, Cortisol, Glucocorticoid metabolism, Obesity, Type 2 diabetes
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
URN: urn:nbn:se:umu:diva-90761DOI: 10.1007/s00125-014-3228-6ISI: 000335922800002PubMedID: 24710966OAI: oai:DiVA.org:umu-90761DiVA: diva2:754382
Available from: 2014-10-10 Created: 2014-07-01 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Stomby, AndreasAndrew, RuthOlsson, Tommy
By organisation
Medicine
In the same journal
Diabetologia
Public Health, Global Health, Social Medicine and Epidemiology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 73 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf